Ian Robert Hardcastle

This inventor holds 16 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Cancer Therapeutics. Top assignees: Cancer Research Technology Limited, Astex Therapeutics Limited, Kudos Pharmaceuticals Limited. Active years: 2006-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ian Robert Hardcastle. Retrieved from https://idiyas.com/inventor/ian-robert-hardcastle

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 4)

% Patents Active = 62.5

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 12.0

ph-index = 6

Forward Citations = 69(Granted Patents)

Location History:

Newcastle Upon Tyne, JP (2006)
Newcastle upon Tyne, GB (2007 - 2010)
Tyne, GB (2012)
Hexham, GB (2013 - 2024)

Company Filing History:

15 out of 269

Cancer Research Technology Limited

patents

5 out of 126

Astex Therapeutics Limited

patents

3 out of 36

Kudos Pharmaceuticals Limited

patents

4. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

Areas of Expertise:

Isoindolinone

MDM2-P53

ERK5

Pyrrolcarboxamide

DNA-PK

Thiopyrane

Anticancer

Therapeutic Agents

Inhibitors

Protein Kinase

Derivatives

Cancer

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071429 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2024-08-27),

2. 11261171 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2022-03-01),

3. 10981898 - Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity (2021-04-20),

4. 10544132 - Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity (2020-01-28),

5. 10526311 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2020-01-07),

6. 10414726 - Therapeutic agents (2019-09-17),

7. 10344017 - Pyrrolcarboxamide derivatives for the inhibition of ERK5 (2019-07-09),

8. 9358222 - Therapeutic agents (2016-06-07),

9. 8618158 - Therapeutic agents (2013-12-31),

10. 8258175 - Isoindolin-1-one derivatives (2012-09-04),

11. 7732483 - DNA-PK inhibitors (2010-06-08),

12. 7696203 - DNA-PK inhibitors (2010-04-13),

13. 7674823 - DNA-PK inhibitors (2010-03-09),

14. 7402607 - DNA-PK inhibitors (2008-07-22),

15. 7226918 - DNA-PK inhibitors (2007-06-05),

Of course! Here is the article about inventor Ian Robert Hardcastle:

Title: Ian Robert Hardcastle: Pioneering Innovations in Cancer Treatment

Introduction: Ian Robert Hardcastle, a prolific inventor hailing from Hexham, GB, has made significant contributions to the field of cancer research and treatment through his groundbreaking patents.

Latest Patents: Ian Robert Hardcastle's latest patents revolve around “Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity.” These patents entail a novel compound formula that shows promise in combating cancer. The inventions include compounds, pharmaceutical compositions, processes for manufacturing, and medical applications.

Career Highlights: With an impressive portfolio of 15 patents, Ian Robert Hardcastle has demonstrated his dedication to advancing cancer treatment technologies. He has played a vital role in companies such as Cancer Research Technology Limited and Astex Therapeutics Limited, where his expertise has been instrumental in driving innovation.

Collaborations: Throughout his career, Ian Robert Hardcastle has collaborated with esteemed professionals in the field, including notable individuals like Bernard Thomas Golding and Roger John Griffin. These collaborative efforts have led to the development of cutting-edge solutions in cancer therapeutics.

Conclusion: Ian Robert Hardcastle's unwavering commitment to pioneering innovations in cancer treatment has solidified his reputation as a respected inventor in the industry. His patents not only showcase his technical prowess but also highlight his passion for making a tangible impact on healthcare.

Profile summary based on public USPTO records.